An article about an AI-designed small-molecule drug candidate for several eye disorders, explaining the discovery approach and preclinical development path.
Key Takeaways
- Insilico nominated ISM9077 as a preclinical candidate for multiple ocular inflammatory and degenerative diseases
- Preclinical data showed ISM9077 had higher retinal exposure than plasma and supported oral or topical delivery
- Molecule was designed and optimized with the Chemistry42 generative AI platform and progressed to PCC nomination rapidly